Diabetic Macular Edema- Pipeline Insight, 2025
Description
DelveInsight’s, “Diabetic Macular Edema- Pipeline Insight, 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diabetic Macular Edema: Overview
Diabetic Macular Edema (DME) is a complication of diabetic retinopathy, a condition caused by diabetes affecting the blood vessels in the retina. The macula, the central portion of the retina responsible for detailed central vision, becomes swollen due to fluid leakage from damaged blood vessels. This swelling disrupts the macula's function, leading to blurry or distorted vision. DME is one of the leading causes of vision loss in individuals with diabetes.
Signs and symptoms of DME may include blurry or wavy vision, difficulty reading or seeing details, color changes in vision, and even a blank or dark spot in the central vision. As the condition progresses, vision loss can become severe and irreversible. The pathophysiology of DME involves chronic hyperglycemia (high blood sugar levels) damaging the blood vessels in the retina. This damage leads to increased permeability of the blood vessels, allowing fluid to leak into the macula. Additionally, the release of inflammatory molecules and growth factors further contributes to the breakdown of the blood-retinal barrier, exacerbating fluid accumulation and tissue damage.
Several factors can contribute to the development and progression of DME, including the duration and severity of diabetes, uncontrolled blood sugar levels, hypertension, hyperlipidemia, and genetic predisposition. Diabetic retinopathy, particularly its proliferative stage, increases the risk of developing DME. Diagnosis of DME typically involves a comprehensive eye examination, including visual acuity testing, dilated eye exam, optical coherence tomography (OCT) to assess macular thickness and morphology, and fluorescein angiography to visualize blood flow in the retina. Early detection is crucial for timely intervention to prevent vision loss.
Treatment options for DME aim to reduce macular edema, preserve vision, and prevent disease progression. Common interventions include intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications to reduce vascular leakage and inflammation, laser photocoagulation to seal leaking blood vessels, and corticosteroid injections to decrease inflammation. Additionally, optimizing glycemic control and managing systemic risk factors such as hypertension and hyperlipidemia are essential for long-term management and prevention of recurrence. Regular follow-up visits with an ophthalmologist are necessary to monitor disease activity and adjust treatment as needed.
""Diabetic Macular Edema- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Macular Edema pipeline landscape is provided which includes the disease overview and Diabetic Macular Edema treatment guidelines. The assessment part of the report embraces, in depth Diabetic Macular Edema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Macular Edema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diabetic Macular Edema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Macular Edema Emerging Drugs
Further product details are provided in the report……..
Diabetic Macular Edema: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Macular Edema drugs segregated based on following parameters that define the scope of the report, such as:
Diabetic Macular Edema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Macular Edema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Macular Edema drugs.
Diabetic Macular Edema Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Diabetic Macular Edema: Overview
Diabetic Macular Edema (DME) is a complication of diabetic retinopathy, a condition caused by diabetes affecting the blood vessels in the retina. The macula, the central portion of the retina responsible for detailed central vision, becomes swollen due to fluid leakage from damaged blood vessels. This swelling disrupts the macula's function, leading to blurry or distorted vision. DME is one of the leading causes of vision loss in individuals with diabetes.
Signs and symptoms of DME may include blurry or wavy vision, difficulty reading or seeing details, color changes in vision, and even a blank or dark spot in the central vision. As the condition progresses, vision loss can become severe and irreversible. The pathophysiology of DME involves chronic hyperglycemia (high blood sugar levels) damaging the blood vessels in the retina. This damage leads to increased permeability of the blood vessels, allowing fluid to leak into the macula. Additionally, the release of inflammatory molecules and growth factors further contributes to the breakdown of the blood-retinal barrier, exacerbating fluid accumulation and tissue damage.
Several factors can contribute to the development and progression of DME, including the duration and severity of diabetes, uncontrolled blood sugar levels, hypertension, hyperlipidemia, and genetic predisposition. Diabetic retinopathy, particularly its proliferative stage, increases the risk of developing DME. Diagnosis of DME typically involves a comprehensive eye examination, including visual acuity testing, dilated eye exam, optical coherence tomography (OCT) to assess macular thickness and morphology, and fluorescein angiography to visualize blood flow in the retina. Early detection is crucial for timely intervention to prevent vision loss.
Treatment options for DME aim to reduce macular edema, preserve vision, and prevent disease progression. Common interventions include intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications to reduce vascular leakage and inflammation, laser photocoagulation to seal leaking blood vessels, and corticosteroid injections to decrease inflammation. Additionally, optimizing glycemic control and managing systemic risk factors such as hypertension and hyperlipidemia are essential for long-term management and prevention of recurrence. Regular follow-up visits with an ophthalmologist are necessary to monitor disease activity and adjust treatment as needed.
""Diabetic Macular Edema- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Macular Edema pipeline landscape is provided which includes the disease overview and Diabetic Macular Edema treatment guidelines. The assessment part of the report embraces, in depth Diabetic Macular Edema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Macular Edema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Macular Edema R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Macular Edema.
This segment of the Diabetic Macular Edema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Macular Edema Emerging Drugs
- Tarcocimab tedromer: Kodiak sciences
- Aganirsen: Gene Signal
- K8: Inflammasome Therapeutics
Further product details are provided in the report……..
Diabetic Macular Edema: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Macular Edema drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diabetic Macular Edema
- There are approx. 45+ key companies which are developing the therapies for Diabetic Macular Edema. The companies which have their Diabetic Macular Edema drug candidates in the most advanced stage, i.e. phase III include, Kodiak sciences.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Diabetic Macular Edema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Macular Edema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Macular Edema drugs.
Diabetic Macular Edema Report Insights
- Diabetic Macular Edema Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic Macular Edema drugs?
- How many Diabetic Macular Edema drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Macular Edema?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Macular Edema therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic Macular Edema and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kodiak sciences
- Gene Signal
- Inflammasome Therapeutics
- Celltrion
- Mylan Pharmaceuticals
- 4D Molecular Therapeutics
- Adverum Biotechnologies, Inc.
- Opthea Limited
- Innovent Biologics (Suzhou) Co. Ltd.
- Lanyue Biotech (Hangzhou) Co., Ltd
- AbbVie
- Frontera Therapeutics
- Hoffmann-La Roche
- Unity Biotechnology, Inc.
- Clearside Biomedical
- Oxurion
- OcuTerra Therapeutics
- Tarcocimab tedromer
- Aganirsen
- K8
- CT-P42
- MYL-1701P
- 4D-150 IVT
- ADVM-022
- OPT-302
- IBI324
- SKG0106
- RGX-314
- FT-003
- Vamikibart
- UBX1325
- Triamcinolone acetonide suprachoroidal injectable suspension
- THR-149
- Nesvategrast
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Diabetic Macular Edema: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Diabetic Macular Edema– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Tarcocimab tedromer: Kodiak sciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Aganirsen: Gene Signal
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- K8: Inflammasome Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Diabetic Macular Edema Key Companies
- Diabetic Macular Edema Key Products
- Diabetic Macular Edema- Unmet Needs
- Diabetic Macular Edema- Market Drivers and Barriers
- Diabetic Macular Edema- Future Perspectives and Conclusion
- Diabetic Macular Edema Analyst Views
- Diabetic Macular Edema Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
